SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

All News Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-06 pm EDT			5-day change	1st Jan Change
11.89 ^CNY	+1.62%		+9.28%	+21.45%

Apr. 29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16	MT
China stocks rise after new guidelines; HK shares drop	Apr. 15	RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	Mar. 07	MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	Jan. 03	MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	Dec. 08	MT
Shyndec Pharma Passes Drug GMP Compliance Inspection	Nov. 28	MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	Nov. 08	MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	Nov. 07	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	23-09-19	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	23-09-18	CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	23-09-14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-24	CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	23-07-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

All News

Filters